In an attempt to characterize the nature of semantic memory impairment in persons with dementia of the Alzheimer type (DAT), a free association task, a definition task, and an associate rank ordering task were administered to 10 mildly and 13 moderately impaired DAT subjects, and 14 normal control subjects. The DAT subjects presented a free association response profile that was markedly different from normal controls. Further, DAT subjects provided meaningful definitions to many of the words used as stimuli in the free association task. Relative to controls, DAT subjects demonstrated a deterioration in their ability to rank order words according to the strength of their association to a stimulus noun. The presently obtained data suggest that the semantic memory impairment in DAT can be characterized, in part, as a deterioration in the associative structure between concepts and a loss of conceptual knowledge.

The purpose of this investigation was to determine the test-retest response consistency rate on a semantic memory task in persons with dementia of the Alzheimer type (DAT). Ten mildly and 13 moderately impaired DAT subjects and 14 normal controls matched for age, years of education, and estimated IQ participated in this study. The Peabody Picture Vocabulary Test (PPVT) was administered twice to each subject with a seven day inter-test interval. The mild and moderate DAT subjects responded inconsistently to significantly more PPVT items than normal controls. When the effects of guessing were considered, moderate DAT subjects gave significantly more inconsistent PPVT responses than normal controls and mild DAT subjects showed a trend towards giving more inconsistent responses. These results substantiate the conclusion that the impairment of specific conceptual knowledge in DAT subjects cannot be reliably measured with a single administration of a semantic memory task such as the PPVT.

No description available.

No description available.

No description available.

No description available.

No description available.

No description available.

Emerging evidence supports the use of methylphenidate (MPH) for the treatment of apathy in Alzheimer’s disease (AD). This study aimed to investigate the additional effects of MPH on attention in an AD sample and the relationship between apathy and attention. AD patients enrolled in a randomized, double-blind placebo-controlled study to examine the safety and efficacy of MPH (10mg PO twice daily) for the treatment of apathetic symptoms were tested on attention and apathy every 2 weeks for 6 weeks. A mixed effects linear regression revealed attention change scores (endpoint - baseline) over time favouring MPH (δ=1.01, p=0.03), though there were no significant associations between apathy and attention change scores (r=-0.08, p=0.54). These results suggest that while MPH can improve both apathy and attention, the effects appear independent in this patient population. This study provides insight into the different effects MPH can produce in a heterogeneous disease such as AD.

Emerging evidence supports the use of methylphenidate (MPH) for the treatment of apathy in Alzheimer’s disease (AD). This study aimed to investigate the additional effects of MPH on attention in an AD sample and the relationship between apathy and attention. AD patients enrolled in a randomized, double-blind placebo-controlled study to examine the safety and efficacy of MPH (10mg PO twice daily) for the treatment of apathetic symptoms were tested on attention and apathy every 2 weeks for 6 weeks. A mixed effects linear regression revealed attention change scores (endpoint - baseline) over time favouring MPH (δ=1.01, p=0.03), though there were no significant associations between apathy and attention change scores (r=-0.08, p=0.54). These results suggest that while MPH can improve both apathy and attention, the effects appear independent in this patient population. This study provides insight into the different effects MPH can produce in a heterogeneous disease such as AD.